SNDX

SyndaxC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$36.00

+95.8% vs current

Most likely

Base case

45%

Probability

Target price

$29.00

+57.7% vs current

B-

Bear case

25%

Probability

Target price

$16.00

-13.0% vs current

AI sentiment snapshot

Latest data as of 2026-04-17

AI commentary

Deterministic signals lean positive, but this is still best framed as a cautious monitoring name rather than a high-conviction breakout thesis. Evidence quality is decent because the core setup is confirmed by primary company materials, yet the peer set is loose and the main rerating drivers are still launch durability plus one later-stage clinical readout.

RankAlpha Sentiment Codex - 2026-04-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-16eventMAXPIRe idiopathic pulmonary fibrosis topline data in 4Q26High impact

Management said axatilimab's Phase 2 MAXPIRe trial in IPF completed enrollment in 1Q26 and topline data are expected in 4Q26, creating a discrete readout on whether Niktimvo can expand beyond chronic GVHD into a larger fibrotic disease market [#8-K-2026-02-26].

2026-07-16catalystDual-product launch momentum can keep supporting the tapeHigh impact

Syndax exited 2025 with Revuforj 4Q25 net revenue of $44.2M, up 38% vs 3Q25, and Niktimvo net revenue of $56.0M, up 22% vs 3Q25, while management said both products have multiple growth drivers and that current cash plus anticipated revenue can enable profitability [#8-K-2026-02-26].

2027-04-17catalystRevumenib expansion into frontline AML settings remains the main multi-year upsideHigh impact

Syndax has already started REVEAL-ND in newly diagnosed NPM1m AML, has EVOLVE-2 ongoing in newly diagnosed NPM1m and KMT2Ar AML patients unfit for intensive chemotherapy, and expects the RAVEN study to initiate in 2H26, giving Revuforj a credible path beyond current relapsed/refractory labels if data hold [#8-K-2026-02-26].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-17 • Updated nightlySource: Internal modelMethodology